Now showing items 11-12 of 12
Bevacizumab continuation beyond initial bevacizumab progression among recurrent glioblastoma patients.
(Br J Cancer, 2012-10-23)
BACKGROUND: Bevacizumab improves outcome for most recurrent glioblastoma patients, but the duration of benefit is limited and survival after initial bevacizumab progression is poor. We evaluated bevacizumab continuation ...
MRP3: a molecular target for human glioblastoma multiforme immunotherapy.
(BMC Cancer, 2010-09-01)
BACKGROUND: Glioblastoma multiforme (GBM) is refractory to conventional therapies. To overcome the problem of heterogeneity, more brain tumor markers are required for prognosis and targeted therapy. We have identified and ...